BACKGROUND: The study investigated whether tumor volume changes at 8 weeks of therapy is associated with outcomes in advanced non-small-cell lung cancer (NSCLC) patients harboring sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs). METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. RESULTS: Among 56 eligible patients, the median tumor volume was 17.8 cm (range, 1.3-172.7 cm) on the baseline scans. Forty-nine patients had follow-up computed tomography at approximately 8 weeks; the median tumor volume at 8 weeks was 7.1 cm (range, 0.4-62.3 cm), with the median proportional volume change of -59% (range, -90% to +91%) from baseline. The proportional volume change at 8 weeks was associated with survival (p = 0.02). Using the cutoff value of 38% volume decrease (75th percentile) at 8 weeks, patients with volume decrease more than 38% (n = 37) had a median overall survival of 43.5 months compared with 16.3 months among those with volume decrease of 38% or less (n = 12; p = 0.01). The median progression-free survival for patients with more than 38% volume decrease was 12.6 months, compared with 5.5 months for those with 38% or lesser volume decrease (p = 0.2). CONCLUSION: The proportional volume change at 8 weeks is associated with overall survival in EGFR-mutant advanced NSCLC patients treated with first-line EGFR-TKIs. The observation of the study, if confirmed in larger study cohorts, indicates that tumor volume analysis at 8 weeks may provide an early marker for survival, and contribute to therapeutic decision making by identifying patients who may benefit from additional anticancer therapy after 8 weeks of EGFR-TKI therapy.
BACKGROUND: The study investigated whether tumor volume changes at 8 weeks of therapy is associated with outcomes in advanced non-small-cell lung cancer (NSCLC) patients harboring sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs). METHODS: In 56 advanced NSCLCpatients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. RESULTS: Among 56 eligible patients, the median tumor volume was 17.8 cm (range, 1.3-172.7 cm) on the baseline scans. Forty-nine patients had follow-up computed tomography at approximately 8 weeks; the median tumor volume at 8 weeks was 7.1 cm (range, 0.4-62.3 cm), with the median proportional volume change of -59% (range, -90% to +91%) from baseline. The proportional volume change at 8 weeks was associated with survival (p = 0.02). Using the cutoff value of 38% volume decrease (75th percentile) at 8 weeks, patients with volume decrease more than 38% (n = 37) had a median overall survival of 43.5 months compared with 16.3 months among those with volume decrease of 38% or less (n = 12; p = 0.01). The median progression-free survival for patients with more than 38% volume decrease was 12.6 months, compared with 5.5 months for those with 38% or lesser volume decrease (p = 0.2). CONCLUSION: The proportional volume change at 8 weeks is associated with overall survival in EGFR-mutant advanced NSCLCpatients treated with first-line EGFR-TKIs. The observation of the study, if confirmed in larger study cohorts, indicates that tumor volume analysis at 8 weeks may provide an early marker for survival, and contribute to therapeutic decision making by identifying patients who may benefit from additional anticancer therapy after 8 weeks of EGFR-TKI therapy.
Authors: Binsheng Zhao; Geoffrey R Oxnard; Chaya S Moskowitz; Mark G Kris; William Pao; Pingzhen Guo; Valerie M Rusch; Marc Ladanyi; Naiyer A Rizvi; Lawrence H Schwartz Journal: Clin Cancer Res Date: 2010-06-09 Impact factor: 12.531
Authors: Mizuki Nishino; Mengye Guo; David M Jackman; Pamela J DiPiro; Jeffrey T Yap; Tak K Ho; Hiroto Hatabu; Pasi A Jänne; Annick D Van den Abbeele; Bruce E Johnson Journal: Acad Radiol Date: 2010-10-30 Impact factor: 3.173
Authors: David M Jackman; Beow Y Yeap; Lecia V Sequist; Neal Lindeman; Alison J Holmes; Victoria A Joshi; Daphne W Bell; Mark S Huberman; Balazs Halmos; Michael S Rabin; Daniel A Haber; Thomas J Lynch; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne Journal: Clin Cancer Res Date: 2006-07-01 Impact factor: 12.531
Authors: Binsheng Zhao; Lawrence H Schwartz; Chaya S Moskowitz; Liang Wang; Michelle S Ginsberg; Cathleen A Cooper; Li Jiang; John P Kalaigian Journal: Radiology Date: 2005-01-28 Impact factor: 11.105
Authors: Pasi A Jänne; Xiaofei Wang; Mark A Socinski; Jeffrey Crawford; Thomas E Stinchcombe; Lin Gu; Marzia Capelletti; Martin J Edelman; Miguel A Villalona-Calero; Robert Kratzke; Everett E Vokes; Vincent A Miller Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Maria E Arcila; Geoffrey R Oxnard; Khedoudja Nafa; Gregory J Riely; Stephen B Solomon; Maureen F Zakowski; Mark G Kris; William Pao; Vincent A Miller; Marc Ladanyi Journal: Clin Cancer Res Date: 2011-01-19 Impact factor: 12.531
Authors: Primo N Lara; Mary W Redman; Karen Kelly; Martin J Edelman; Stephen K Williamson; John J Crowley; David R Gandara Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Jänne; Thomas Lynch; Bruce E Johnson; Vincent A Miller Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Mizuki Nishino; Adrian G Sacher; Leena Gandhi; Zhao Chen; Esra Akbay; Andriy Fedorov; Carl F Westin; Hiroto Hatabu; Bruce E Johnson; Peter Hammerman; Kwok-Kin Wong Journal: Eur J Radiol Date: 2016-12-26 Impact factor: 3.528
Authors: Mizuki Nishino; Anita Giobbie-Hurder; Michael P Manos; Nancy Bailey; Elizabeth I Buchbinder; Patrick A Ott; Nikhil H Ramaiya; F Stephen Hodi Journal: Clin Cancer Res Date: 2017-06-07 Impact factor: 12.531
Authors: Mizuki Nishino; Suzanne E Dahlberg; Linnea E Fulton; Subba R Digumarthy; Hiroto Hatabu; Bruce E Johnson; Lecia V Sequist Journal: Acad Radiol Date: 2016-01-08 Impact factor: 3.173
Authors: Mizuki Nishino; Suzanne E Dahlberg; Stephanie Cardarella; David M Jackman; Michael S Rabin; Nikhil H Ramaiya; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson Journal: Cancer Date: 2013-08-06 Impact factor: 6.860
Authors: Mizuki Nishino; Suzanne E Dahlberg; Anika E Adeni; Christine A Lydon; Hiroto Hatabu; Pasi A Jänne; F Stephen Hodi; Mark M Awad Journal: Clin Cancer Res Date: 2017-07-05 Impact factor: 12.531